iwNHL 2014 Highlights

September 5th – 7th 2014

Applying myeloma knowledge in lymphoma

Dr Rafael Fonseca, Prof Keith Stewart and Prof Leif Bergsagel

Dr Rafael Fonseca (Mayo Clinic, Arizona, USA) interviews Prof Keith Stewart (Mayo Clinic, Arizona, USA) and Prof Leif Bergsagel (Mayo Clinic, Arizona, USA), all doctors with an interest in myeloma, about the application of myeloma biology and therapies in lymphoma.

Prof Stewart describes tumour heterogeneity and suggests a parallel between myeloma and indolent follicular lymphoma, where the presence of a more aggressive tumour subclone may have significant clinical implications.

Prof Bergsagel describes the contribution of MYC to tumour heterogeneity and poor prognosis. Targeting the interaction between the immune system and tumour may provide new therapies.

view video

Lymphoma microenvironment: biology and therapy

Prof John Gribben and Prof Randy Gascoyne

Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumour biology and therapy.

Part - 1

The interaction between tumour cells and non-tumour cells has been increasingly recognised to contribute to disease progression.

view video

Part - 2

Improved trial designs, consideration of clinical variables and use of higher resolution approaches are recommended to overcome current research limitations in this field.

view video

Part - 3

Understanding the biology of the lymphoma microenvironment may allow rational therapeutic targeting. Emerging clinical studies in this field are reviewed. The immune system is presented as a potential and attractive target to disrupt the interaction between the tumour and non-tumour microenvironment cells, with a focus on lenalidomide and rituximab immunotherapy.

view video

Update: diffuse large B-cell lymphoma

Prof Michael Pfreundschuh, Dr Rich Fisher and Prof Christian Gisselbrech

Prof Michael Pfreundschuh (Saarland University Medical School, Homburg, Germany), Dr Rich Fisher (Fox Chase Cancer Center, Pennsylvania, USA) and Prof Christian Gisselbrecht (Hôpital Saint-Louis, Paris, France) discuss the biology and management of diffuse large B-cell lymphoma (DLBCL).

Dr Fisher describes the difficulties in defining and managing patients who are not cured by standard therapy. The classification of DLBCLs is an important consideration for research studies and clinical management. ‘Double-hit’ lymphomas have poor prognosis and management options are discussed.

Prof Gisselbrecht describes important recent advances in treatment options for different DLBCL subtypes. Future research directions and their impact on patients are also examined.

view video

Update: mantle cell lymphoma

Prof Susan O’Brien and Prof Eva Kimby

Prof Susan O’Brien (MD Anderson Cancer Center, Texas, USA) and Prof Eva Kimby (Karolinska Institutet, Huddinge, Sweden) provide an overview of mantle cell lymphoma. Current treatment strategies are discussed.

There is a focus on ibrutinib therapy for patients who relapse after first-line therapy and a comparison is made with its use in treating chronic lymphocytic leukaemia. Future trial and clinical directions are also examined.

view video

Update: peripheral T-cell lymphoma

Prof Francesco D'Amore, Dr Elaine Jaffe and Prof Laurence de Leval

Prof Francesco D'Amore (Aarhus University, Aarhus, Denmark) interviews Dr Elaine Jaffe (National Cancer Institute, Maryland, USA) and Prof Laurence de Leval (IUP Institut universitaire de pathologie, Lausanne, Switzerland) about their involvement at the iwNHL 2014.

Dr Jaffe describes the important abnormal contribution of B-cell proliferation in angioimmunoblastic T-cell lymphoma and other T-cell lymphomas of follicular T-helper cell derivation. As a result, a neoplastic precursor cell is speculated. Prof de Leval describes recent sequencing discoveries in peripheral T-cell lymphomas that have provided new insight in tumour understanding.

view video

Update: targeted or chemotherapy-free therapies

Prof John Gribben, Prof Wolfram Brugger and Dr Myron Czuczman

Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Wolfram Brugger (University of Freiburg, Villingen-Schwenningen, Germany) and Dr Myron Czuczman (Roswell Park Cancer Institute, New York, USA) about the current and future clinical application of targeted or chemotherapy-free therapies in lymphoma.

They discuss their experiences and some of the challenges of these therapies in clinical practice. It is emphasised that targeted therapies should not necessarily be used as standalone approaches. Combinations of targeted therapies and conventional therapies should be considered, and emerging clinical trials investigating combinations are described. The use of patient's age to determine therapeutic approach may not be appropriate; it is important to find the right therapy for individual patients.

view video

16th International Workshop on Non-Hodgkin Lymphoma

Nice, France



2018 Meeting


Hotel Le Meridien
1 Prom. des Anglais, 06046 Nice, France

© 2014 - 2019 World Health Communications Ltd